Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 19/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 19/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 18/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662987 | 0.81 | ESR1 (0.52) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| SCHEMBL13380548 | 0.81 | ESR1 (0.52) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| SCHEMBL3567530 | 0.81 | ESR1 (0.52) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| Iodide SCHEMBL27708171 | 0.80 | ESR1 (0.51) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| SCHEMBL10293570 | 0.80 | ADRA2A (0.52) | ADRA2AADRA2CADRA2B | |
| SCHEMBL17898055 | 0.80 | ADRA2A (0.52) | ADRA2AADRA2CADRA2B | |
| SCHEMBL81498 | 0.80 | ADRA2A (0.52) | ADRA2AADRA2CADRA2B | |
| SCHEMBL24518340 | 0.79 | CDK4 (0.47) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| SCHEMBL1814699 | 0.79 | ADRA2C (0.56) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| SCHEMBL188069 | 0.79 | ADRA2C (0.56) | ADRA2AADRA2CADRA2BESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | ADRA2A 2825/4885ADRA2C 1807/4885ADRA2B 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.